Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.
OBJECTIVE
Black patients may be less responsive to beta-blockers than whites. Genetic variants in the beta1-adrenergic receptor (beta1-AR) associated with lesser response to beta-blockers are more common in blacks than in whites. The purpose of this study was to determine whether ethnic differences in response to beta-blockade can be explained by differing distributions of functional genetic variants in the beta1-AR.


METHODS
We measured sensitivity to beta-blockade by the attenuation of exercise-induced tachycardia in 165 patients (92 whites), who performed a graded bicycle exercise test before and 2.5 h after oral atenolol (25 mg). We determined heart rate at rest and at three exercise levels from continuous ECG recordings and calculated the area under the curve. We also measured plasma atenolol concentrations and determined genotypes for variants of the beta1-AR (Ser49Gly, Arg389Gly) and alpha2C-AR (del322-325). The effects of ethnicity, genotype, and other covariates on the heart rate reduction after atenolol were estimated in multiple regression analyses.


RESULTS
Atenolol resulted in a greater reduction in exercise heart rate in whites than in blacks (P=0.006). beta1-AR Arg389 (P=0.003), but not the alpha2C-AR 322-325 insertion allele (P=0.31), was independently associated with a greater reduction in heart rate area under the curve. Ethnic differences in sensitivity to atenolol remained significant (P=0.006) after adjustment for beta1-AR and alpha2C-AR genotypes.


CONCLUSIONS
Ethnic differences in sensitivity to the beta1-blocker atenolol persist even after accounting for different distributions of functional genetic beta1-AR variants, suggesting that additional, as yet unidentified factors contribute to such ethnic differences.
Kurnik
Daniel
D
Department of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.
Li
Chun
C
Sofowora
Gbenga G
GG
Friedman
Eitan A
EA
Muszkat
Mordechai
M
Xie
Hong-Guang
HG
Harris
Paul A
PA
Williams
Scott M
SM
Nair
Usha B
UB
Wood
Alastair J J
AJ
Stein
C Michael
CM
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D001262:Atenolol / Q000494:pharmacology; D044383:Black People; D005260:Female; D005786:Gene Expression Regulation; D014644:Genetic Variation; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D010597:Pharmacogenetics / Q000379:methods; D011110:Polymorphism, Genetic; D018341:Receptors, Adrenergic, alpha-2 / Q000235:genetics; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics*; D013610:Tachycardia / Q000208:ethnology* / Q000235:genetics*; D044465:White People
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D018341:Receptors, Adrenergic, alpha-2; D018342:Receptors, Adrenergic, beta-1; D001262:Atenolol
Am J Hypertens. 1992 Jan;5(1):37-44
1736933
Pharmacogenet Genomics. 2007 Apr;17(4):277-82
17496726
Eur J Clin Pharmacol. 1988;34(4):363-8
2900144
Pharmacol Rev. 2004 Mar;56(1):31-52
15001662
Clin Pharmacol Ther. 2003 Oct;74(4):372-9
14534524
Pharmacogenet Genomics. 2005 Mar;15(3):137-42
15861037
Methods Mol Biol. 2003;212:129-47
12491907
Pharmacogenet Genomics. 2005 Apr;15(4):227-34
15864115
S Afr Med J. 1982 Nov 27;62(23):849-50
6755764
Pharmacogenet Genomics. 2005 Mar;15(3):143-9
15861038
Clin Pharmacol Ther. 2003 Apr;73(4):366-71
12709726
Bioinformatics. 2005 May 1;21(9):2128-9
15705655
N Engl J Med. 2002 Oct 10;347(15):1135-42
12374873
J Biol Chem. 2000 Jul 28;275(30):23059-64
10801795
JAMA. 1982 Oct 22;248(16):1996-2003
6750166
Clin Pharmacol Ther. 2004 Dec;76(6):536-44
15592325
Clin Pharmacol Ther. 1995 Jun;57(6):678-83
7781268
Hypertension. 2004 Jun;43(6):1166-7
15117911
Clin Pharmacol Ther. 1976 Nov;20(5):524-34
10125
Nat Med. 2003 Oct;9(10):1300-5
14502278
Arch Intern Med. 2003 Mar 10;163(5):525-41
12622600
JAMA. 1986 Oct 24-31;256(16):2214-21
3531560
Eur J Hum Genet. 2005 Mar;13(3):341-51
15523499
N Engl J Med. 1998 Aug 20;339(8):489-97
9709041
N Engl J Med. 2001 May 3;344(18):1392-3
11333999
Pharmacogenetics. 2001 Mar;11(2):95-110
11266083
J Cardiovasc Pharmacol. 1995 Jan;25(1):90-6
7723360
N Engl J Med. 1993 Apr 1;328(13):914-21
8446138
Eur Heart J. 1989 Jun;10 Suppl B:22-8
2553409
Arch Intern Med. 2000 Mar 27;160(6):825-31
10737282
Eur J Heart Fail. 2003 Aug;5(4):463-8
12921807
J Biol Chem. 1999 Apr 30;274(18):12670-4
10212248
Ann Hum Genet. 2006 Sep;70(Pt 5):566-73
16907703
N Engl J Med. 2001 May 31;344(22):1659-67
11386264
Clin Pharmacol Ther. 2003 Jul;74(1):44-52
12844134
J Biol Chem. 2002 Aug 23;277(34):30429-35
12034720
Clin Pharmacol Ther. 2006 Jul;80(1):23-32
16815314
J Cardiovasc Pharmacol. 1984 Mar-Apr;6(2):361-4
6200729
Hum Mutat. 1999 Sep 19;14(3):271
10477438
Clin Pharmacol Ther. 2003 Oct;74(4):299-302
14534516
Eur Heart J. 2004 Aug;25(15):1341-62
15288162
J Hum Hypertens. 1991 Jun;5(3):193-8
1920342
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-93
16844790
J Hypertens. 2007 Apr;25(4):763-71
17351367
Xenobiotica. 1978 May;8(5):313-20
27019